菜单
CRO Services

Drug Development Expertise Empowering Research Services for Biologics

Hybridoma


Advanced Hybridoma Platform Compatible with Multiplexed Functional Assays

We offer fully human antibody generation through transgenic animals, enabling fast-track, high-quality lead identification. With a proven track record of successfully delivering over 300 discovery projects using hybridoma technology, our team has developed cutting-edge methods to maximize success rates from immunization to fusion & screening.

 

 

Key Features of Hybridoma Platform:

Immunization

  • AAALAC-accredited facilities ensuring ethical and high-quality animal care
  • Tailored methods to overcome immune tolerance
  • Custom immunogen design and generation for diverse targets and applications, including DNAs, peptides, proteins, cells, and mRNAs

 

Fusion & Screening

  • High fusion efficiency using electrofusion technology
  • Over 4,000 single clones obtained directly from fusion
  • Subcloning skipped to save 2 weeks without compromising monoclonality
  • High-throughput screening platforms, including:
    • Binding assays using ELISA and FACS
    • Reporter gene assays (RGAs) for functional screening
    • Internalization assays supporting ADC discovery
  • High-throughput binding and ranking capabilities with 5 flow cytometers, 9 Biacore, and 1 Carterra.

Hybridoma Service Details:

Service Item Turnaround Time Request A Quote 
Immunization 4-12 weeks Request A Quote
Fusion & Screening 2-4 weeks
Hybridoma Sequencing 1-2 weeks

Case Study #1: Discovery and Characterization of a Therapeutic Monoclonal Antibody for ADC Development

High-throughput screening and in vitro characterization was conducted to identify and optimize a mAb with superior internalization, high-affinity binding, and effective cytotoxicity when conjugated to MMAE. Our hybridoma-based, high-throughput internalization screening and lead characterization assays enabled the selection of optimal ADC leads with comparable or improved performance to benchmark antibodies.

 

High-throughput screening for monoclonal antibody discovery, using pHrodo assay and FACS-based acid quenching.

Figure A: High-throughput internalization screening of hybridoma-derived antibodies using the pHrodo assay. Herceptin demonstrated dose-dependent internalization in HER-2 expressing SK-BR-3 cells, serving as a positive control. FACS-based acid quenching internalization screening was used to compare to antibody 1 and antibody 2. Antibody 1 exhibited a higher internalization, making it a stronger candidate for ADC.

Internalization activity, epitope binning, and cytotoxicity assays of lead antibodies confirmed potential ADC therapeutic development.

Figure B: Internalization activity of lead antibodies compared to the benchmark (BMK1) in tumor cells, demonstrating comparable internalization efficiency. Dose-dependent epitope binning of lead antibodies with BMK1 confirmed antibodies with diverse binding epitopes were isolated from the screening campaign. Dose-dependent cytotoxicity of ADC candidates (Fab-MMAE conjugates) showed comparable cytotoxicity to the benchmark, confirming its potential for ADC therapeutics development.

Case Study #2: Discovery of a Monoclonal Antibody for Immunohistochemistry (IHC) Staining

We employed hybridoma discovery technology and characterization studies to identify high-affinity monoclonal antibodies for immunohistochemistry (IHC) applications. Using ELISA-based screening and IHC validation, our platform enabled the selection of optimal mAb leads with high affinity and binding performance.

 

ELISA serum titer detection show dose-dependent binding of antibodies to extracellular protein fragments of CD3.

Figure A: Serum titer detection by ELISA, showing dose-dependent binding of antibodies against extracellular protein fragments of CD3. Mice were immunized with recombinant extracellular protein fragments to generate high-affinity monoclonal antibodies.

Dose-dependent binding curves show strong and comparable binding activity of candidate 1 and candidate 2 against extracellular protein fragments of CD3.

Figure B: Dose-dependent binding curves of mAbs against extracellular protein fragments of CD3, demonstrating strong and comparable binding activity between candidate 1 and candidate 2.

IHC staining showed higher intensity and sensitivity for candidate 1 compared to candidate 2 for IHC applications.

Figure C: Immunohistochemistry (IHC) staining results for two monoclonal antibody candidates at different concentrations. Candidate 1 displayed higher staining intensity and sensitivity compared to candidate 2, confirming its suitability for IHC staining applications.

Case Study #3: Advanced Anti-Idiotype Antibody Discovery through Hybridoma Technology

This case study showcases our hybridoma-based anti-idiotype antibody discovery, spanning immunization, fusion & screening, hybridoma sequencing, and recombinant antibody production and characterization, resulting in high-affinity binding, distinct blocking and non-blocking profiles, and quantitative ELISA validation with a linear standard curve for pharmacokinetics (PK) assay development.

 

Hybridoma-based anti-idiotype antibody discovery results showing binding, blocking activity, and quantitative ELISA validation for high-affinity antibody screening.

Figure 1: Anti-idiotype antibody discovery through hybridoma technology showing (A) high binding affinity (sub-nanomolar EC50) against a mAb drug in 20% human serum, (B) blocking (sub-nanomolar IC50) vs. non-blocking profiles, and (C) quantitative ELISA and linear standard curve with double digit picomolar detection limit.

 

Your Project. Our Expertise.